Patent EP0219076A2 successfully refreshed from Google Patents.
EP0219076A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Sustained release composition
Assignee: Sumitomo Pharma Co Ltd
•
Filing: 1986-10-10
•
Granted: —
•
Expires: 2006-10-10
Abstract
Abstract A sustained release composition applicable for human beings and mammals which comprises (a) a silicone elastomer and (b) a pharmaceutical substance optionally with (c) albumin. When the pharmaceutical substance is of high molecular weight and can exert its pharmaceutical effect in a trace amount, its continuous release over a long period is attained by application of this invention.
Inventors
- 👤 Keiji Fujioka
- 👤 Shigeji Sato
- 👤 Nobuhiko Tamura
- 👤 Yoshihiro Takada
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-10-23 23:38
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/20; A61K9/2004; A61K9/2022; A61K9/2031; A61K9/2036; A61K9/0012; A61K9/0019; A61K9/0024
Claims Analysis
Total Claims: 22
Claim 1
Independent Claim
18 words
A sustained release composition which comprises a silicone elastomer and a high molecular weight pharmaceutical substance contained therein.
Claim 2
Dependent Claim
18 words
A sustained release composition which comprises a silicone elastomer and a high molecular weight pharmaceutical substance contained therein.
Claim 3
Dependent Claim
20 words
A sustained release composition which comprises (a) a silicone elastomer with (b) a pharmaceutical substance except albumin and (c) albumin.
Claim 4
Dependent Claim
20 words
A sustained release composition which comprises (a) a silicone elastomer with (b) a pharmaceutical substance except albumin and (c) albumin.
Claim 5
Dependent Claim
20 words
The composition according to claim 1 or 2, wherein the pharmaceutical substance has a molecular weight of 1,000 to 500,000.&
Claim 6
Dependent Claim
26 words
The composition according to claim 1 or 2, wherein the pharmaceutical substance should be administered in a trace amount continuously over a long period of time.
Claim 7
Dependent Claim
26 words
The composition according to any of claims 1 to 4, wherein the pharmaceutical substance has growth regulating activity, bone metabolizing activity, thrombolytic activity or immunoregulating activity.
Claim 8
Dependent Claim
23 words
The composition according to claim 5, wherein the pharmaceutical substance having growth regulating activity is growth hormone, growth hormone releasing factor or somatomedin.
Claim 9
Dependent Claim
16 words
The composition acording to claim 5, wherein the pharmaceutical substance having bone metabolizing activity is calcitonin.
Claim 10
Dependent Claim
17 words
The composition according to claim 5, wherein the pharmaceutical substance having thrombolytic activity is tissue plasminogen activator.
Claim 11
Dependent Claim
27 words
The composition according to claim 5, wherein the pharmaceutical substance having immunoregulating activity is interferon, interleukin, colony stimulating factor, macrophage activating factor or macrophage migration inhibitory factor.
Claim 12
Dependent Claim
17 words
The composition according to any of claims 2 to 4, wherein the pharmaceutical substance has anti-inflammatory activity.
Claim 13
Dependent Claim
30 words
The composition according to any of claims 1 to 4, wherein the pharmaceutical substance is continuously released over a long period of time from the silicone elastomer as the matrix.
Claim 14
Dependent Claim
39 words
The composition according to any of claims 1 to 4, wherein the pharmaceutical substance charged in a hollow vessel of the silicone elastomer is continuously released over a long period of time through the wall of said hollow vessel.
Claim 15
Dependent Claim
23 words
The composition according to claim 1, wherein the pharmaceutical substance is contained in a content of not more that 15 % by weight.
Claim 16
Dependent Claim
15 words
The composition according to any of claims 1, 3 and 4, which is injectionally administrable.
Claim 17
Dependent Claim
16 words
The composition according to claim 14, which is molded in a cylindrical, needle or tube shape.
Claim 18
Dependent Claim
27 words
The composition according to claim 15, which is shaped in a diameter of not more than 4 mm and a length of not more than 50 mm.
Claim 19
Dependent Claim
23 words
The composition according to claim 2, wherein the pharmaceutical substance is contained in a content of not more than 50 % by weight.
Claim 20
Dependent Claim
22 words
The composition according to claim 2, wherein the albumin is contained in a content of not more than 50 % by weight.
Claim 21
Dependent Claim
15 words
The composition according to any of claims 1, 3 and 4, which comprises further albumin.
Claim 22
Dependent Claim
39 words
The composition according to claim 19, wherein the pharmaceutical substance is contained in a content of not more than 50 % by weight and the albumin is contained in a content of not more than 50 % by weight.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.